Hepatitis C News and Research

Latest Hepatitis C News and Research

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Secretary of Health Everette James today announced five health research grants totaling approximately $20 million will be awarded from Pennsylvania's share of the national tobacco settlement for 2009-2010.

8 Apr 2010

Hepatitis C infection increases risk for developing kidney cancer

Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.

8 Apr 2010

Sinovac Biotech's fourth-quarter sales increase 194%

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and preliminary twelve-month periods ended December 31, 2009.

6 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria, April 14-18, 2010.

6 Apr 2010

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Unilife Corporation today announced it has received from the U.S. Food and Drug Administration 510(k) market clearance for the Unitract™ 1mL Insulin Syringes assembled at its Lewisberry, PA manufacturing facility.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

MinuteClinic launches health condition monitoring services for diabetes, asthma and high cholesterol patients

MinuteClinic, the largest provider of retail-based medical clinics in the United States, has introduced a series of convenient health condition monitoring services to help patients previously diagnosed with diabetes, asthma, high cholesterol and high blood pressure overcome the challenges of living with their conditions. Health condition monitoring is available at MinuteClinic locations in CVS/pharmacy stores in 20 states and the District of Columbia. MinuteClinic is the retail health care division of CVS Caremark (CVS).

2 Apr 2010

Hepatitis C infected donor kidneys thrown away despite urgent need

More than half of donor kidneys in the United State infected with hepatitis C are thrown away, despite the need among hepatitis C patients who may die waiting for an infection-free organ, Johns Hopkins research suggests.

2 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

Liver function tests misinterpreted in majority of children's hospitals

New research led by physician-scientists at University of California, San Diego School of Medicine shows that the test most commonly used to screen pediatric patients for chronic liver disease is often incorrectly interpreted in many children's hospitals throughout the United States.

2 Apr 2010

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, today announced its 2009 year-end financial results.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the fourth quarter and full year ended December 31, 2009.

31 Mar 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Phase 1 SAD study of PSI-938 for HCV initiated

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Secretary of Health announces five health research grants to improve health of Pennsylvanians

Hepatitis C infection increases risk for developing kidney cancer

Sinovac Biotech's fourth-quarter sales increase 194%

PS-targeting antibodies can block HIV virus from entering into certain blood cells

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Request for lift of full clinical hold on Proellex program

MinuteClinic launches health condition monitoring services for diabetes, asthma and high cholesterol patients

Hepatitis C infected donor kidneys thrown away despite urgent need

2010 DDW conference to highlight breakthrough research on GI health

Liver function tests misinterpreted in majority of children's hospitals

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

T-cell cytolytic activity may be effective in clearing HBV infection

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

PhRMA report: 234 medicines in development for special health care needs of children

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in